Eli Lilly Reports Topline Results from P-III (QWINT-1 and QWINT-3) Studies of Efsitora Alfa (Efsitora) for Type 2 Diabetes
Shots:
- QWINT-1 study assessed the safety & efficacy of efsitora (QW) vs insulin glargine (QD) for 52wks. in insulin-naïve T2D adults (n=796) while QWINT-3 trial compared the same b/w efsitora & insulin degludec for 78wks. in T2D adults (n=986) currently on basal insulin
- QWINT-1 reaching its 1EP, depicting non-inferior A1C reduction of 1.31% vs 1.27% (A1C of 6.92% & 6.96%, respectively) in efficacy estimand and 1.19% vs 1.16% (A1C of 7.05% & 7.08%, respectively) in treatment-regimen estimand at wk.52
- QWINT-3 also met its 1EP, showing reduced A1C of 0.86% vs 0.75% (A1C of 6.93% & 7.03%, respectively) in efficacy estimand and 0.81% vs 0.72% (A1C of 6.99% & 7.08%, respectively) in treatment-regimen estimand at wk.26
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports Data from Two P-III (QWINT-2 and QWINT-4) Studies of Efsitora for Treating Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
